Amgen (AMGN) Reports New LUMAKRAS Plus Chemo Data Sep 11, 2023 05:43AM
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC Sep 10, 2023 09:00AM
Amgen (AMGN) To Discuss Application For Lumakras For The Treatment Of KRAS G12C-positive NSCLC At FDA Advisory Committee Meeting Aug 21, 2023 04:01PM
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING Aug 21, 2023 04:00PM
AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS Aug 3, 2023 04:01PM
View Older Stories

Aug 1, 2023 04:00PM AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
Jul 31, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
Jun 21, 2023 09:01AM Amgen (AMGN) Announces Full FDA Approval of BLINCYTO
Jun 21, 2023 09:00AM FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Jun 9, 2023 04:00PM AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Jun 4, 2023 08:00AM AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
Jun 1, 2023 09:00AM AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
May 30, 2023 06:00PM AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
May 26, 2023 04:00PM AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
May 16, 2023 11:32AM Amgen (AMGN) Responds To FTC Action Regarding Proposed Acquisition Of Horizon Therapeutics (HZNP)
May 16, 2023 11:31AM AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
May 9, 2023 09:02AM Amgen (AMGN) And Tscan Therapeutics (TCRX) Announce Collaboration To Identify Novel Targets In Crohn's Disease
May 9, 2023 09:00AM AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
May 9, 2023 09:00AM Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 8, 2023 09:02AM Amgen (AMGN) Reports New PROLIA Data Showing Reduction in Osteoporotic Fracture Risk Compared to Alendronate
May 8, 2023 09:00AM NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
May 3, 2023 04:00PM AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Apr 27, 2023 04:01PM AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
Apr 21, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
Apr 19, 2023 04:45PM Amgen (AMGN) Wins Patent Appeal On Otezla
Apr 19, 2023 04:45PM AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
Mar 9, 2023 05:20PM AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE
Mar 7, 2023 04:00PM AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
Mar 3, 2023 04:00PM AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE
Mar 1, 2023 09:00AM AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Feb 22, 2023 09:04AM Amgen (AMGN) Announces Cardiovascular Study To Evaluate Association Between Lipoprotein And Cardiovascular Risk In African Americans
Feb 22, 2023 09:00AM AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
Feb 9, 2023 04:00PM AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
Feb 2, 2023 09:00AM TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
Jan 31, 2023 04:01PM AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Jan 31, 2023 06:03AM Amgen (AMGN) Announces Amjevita now Available in the US
Jan 31, 2023 06:00AM AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Jan 26, 2023 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 6, 2023 04:00PM AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET
Jan 4, 2023 04:00PM AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Dec 13, 2022 04:01PM Amgen (AMGN) Says Blincyto Added To Consolidation Chemotherapy Significantly Improves Survival In Adult Patients With Measurable Residual Disease-negative B-ALL
Dec 13, 2022 04:00PM BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Dec 12, 2022 07:50PM AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
Dec 12, 2022 06:05AM AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
Dec 1, 2022 09:31AM Amgen (AMGN) Resents New AMG 133 Phase 1 Clinical Data At WCIRDC 2022
Dec 1, 2022 09:30AM AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022
Nov 28, 2022 04:00PM AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
Nov 23, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
Nov 7, 2022 04:16PM Amgen (AMGN) Presents New Repatha Data
Nov 7, 2022 04:16PM AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
Nov 7, 2022 09:00AM AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
Nov 7, 2022 05:42AM Amgen (AMGN) Reports New Phase 2 Data of olpasiran
Nov 6, 2022 06:13PM AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
Nov 4, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
Nov 3, 2022 04:01PM AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
View Older Stories